248 related articles for article (PubMed ID: 32164504)
1. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
3. Annual review of PROTAC degraders as anticancer agents in 2022.
Wang X; Qin ZL; Li N; Jia MQ; Liu QG; Bai YR; Song J; Yuan S; Zhang SY
Eur J Med Chem; 2024 Mar; 267():116166. PubMed ID: 38281455
[TBL] [Abstract][Full Text] [Related]
4. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
5. [Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].
Wu X; Zhao J; Gao Y; Yao Q; Xie J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3628-3643. PubMed ID: 37805843
[TBL] [Abstract][Full Text] [Related]
6. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
7. PROTAC: targeted drug strategy. Principles and limitations.
Koroleva OA; Dutikova YV; Trubnikov AV; Zenov FA; Manasova EV; Shtil AA; Kurkin AV
Russ Chem Bull; 2022; 71(11):2310-2334. PubMed ID: 36569659
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
[TBL] [Abstract][Full Text] [Related]
9. The state of the art of PROTAC technologies for drug discovery.
Wang C; Zheng C; Wang H; Zhang L; Liu Z; Xu P
Eur J Med Chem; 2022 May; 235():114290. PubMed ID: 35307618
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
11. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Small Molecule PROTACs for the Treatment of Cancer.
Li W; Elhassan RM; Hou X; Fang H
Curr Med Chem; 2021; 28(24):4893-4909. PubMed ID: 33208057
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances of Degradation Technologies Based on PROTAC Mechanism.
Xiao M; Zhao J; Wang Q; Liu J; Ma L
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139095
[TBL] [Abstract][Full Text] [Related]
14. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
[TBL] [Abstract][Full Text] [Related]
15. Degradation of proteins by PROTACs and other strategies.
Wang Y; Jiang X; Feng F; Liu W; Sun H
Acta Pharm Sin B; 2020 Feb; 10(2):207-238. PubMed ID: 32082969
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
17. Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
Lei H; Wang W; Wu Y
Leuk Lymphoma; 2018 Oct; 59(10):2297-2304. PubMed ID: 29198160
[TBL] [Abstract][Full Text] [Related]
18. PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Kelm JM; Pandey DS; Malin E; Kansou H; Arora S; Kumar R; Gavande NS
Mol Cancer; 2023 Mar; 22(1):62. PubMed ID: 36991452
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
20. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]